Tegaserod coadministration does not alter the pharmacokinetics of theophylline in healthy subjects

Journal of Clinical Pharmacology

Volumn 41, Issue 9, 2001, Pages 987-993

  Zhou, H ^a   Khalilieh, S ^a   Svendsen, K ^a   Pommier, F ^a   Osborne, S ^a   Appel Dingemanse, S ^a   Lasseter, K ^a   McLeod, J F ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 INHIBITOR; SEROTONIN 4 AGONIST; TEGASEROD; THEOPHYLLINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG SAFETY; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN EXPERIMENT; IRRITABLE COLON; KIDNEY CLEARANCE; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; TREMOR; VERTIGO;

ADOLESCENT; ADULT; ALGORITHMS; AREA UNDER CURVE; BIOTRANSFORMATION; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP1A2; DRUG INTERACTIONS; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INDOLES; MALE; MIDDLE AGED; THEOPHYLLINE;

EID: 0034873723     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700122010979     Document Type: Article

References (33)

1. 4 receptor agonist, in a model of slow colonic transit
2. The properties of a new prokinetically active drug, SDZ HTF 919
3. SDZ HTF 919 stimulates canine colonic motility and transit in vivo
4. 4 receptor agonist, increases postoperative gastric and small intestinal motility in rats
5. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome
6. 4 receptor agonist
7. 4 receptor agonist induces cAMP-mediated CL-efflux from rat colonocytes
8. 4 agonist (HTF 919) improves symptoms in constipation-predominant irritable bowel syndrome (C-IBS)
9. 4 receptor partial agonist HTF 919 reduces acid exposure in patients with gastroesophageal reflux disease (GERD)
10. Characterization of human liver cytochromes P-450 involved in theophylline metabolism
11. Drug interactions and the cytochrome P450 system: The role of cytochrome P450 1A2
12. Theophylline metabolism in human liver microsomes: Inhibition studies
13. Griseofulvin and fluvoxamine interactions with the metabolism of theophylline
14. Drugs used in asthma
15. Oral vs inhaled asthma therapy: Pros, cons and combinations
16. Gastro-oesophageal reflux disease and asthma
17. Irritable bowel syndrome, gastro-oesophageal reflux, and bronchial hyperresponsiveness in the general population
18. Most asthmatics have gastroesophageal reflux with or without bronchodilator therapy
19. In vitro metabolism of tegaserod in human liver and intestine: Assessment of drug interactions
20. Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919)
21. Simultaneous determination of theophylline and its major metabolites in urine by reverse-phase ion-pair high-performance liquid chromatography
22. Determination of theophylline and its metabolites in plasma and urine by reverse-phase liquid chromatography using an amine modifier
23. 4 receptor agonist, following oral and intravenous administration
24. Metabolism of theophylline by cDNA-expressed human cytochromes P-450
25. Theophylline N-demethylations as probes for P4501A1 and P4501A2
26. A drug interaction between zafirlukast and theophylline
27. Verapamil-induced inhibition of theophylline elimination in healthy humans
28. The influence of caffeine on the steady-state pharmacokinetics of theophylline
29. Enhancement of theophylline clearance by oral albuterol
30. Inhibition of theophylline elimination by diltiazem therapy
31. Elimination of theophylline metabolites in healthy adults
32. Theophylline pharmacokinetics following single and repeated administration of slow-release capsules
33. Comparison of single and multiple dose pharmacokinetics of theophylline using stable isotopes